A study carried out by Ashfield MedComms of 50 medical affairs professionals in the US and Europe, highlighted that a lack of resources, tools and systems was creating a barrier to implementing omnichannel. The study, which was recently referenced in an article in PMLive, explains that there is a desire to leverage the data that omnichannel offers, but the gap between aspiration and reality needs to close. With varying degrees of expertise within pharma, the priority should be to utilise their existing agency relationships which offer a quick and cost-effective approach.
Tangent90 focus on channel-agnostic enablement of scientific copyright content distribution. Working in partnership with publishers, our market-leading solutions are a great addition to the omnichannel toolbox for medical, allowing MSLs to lead the engagement with original published content that has demonstrated impact. With HCPs citing published scientific content in its original form as both highly likely to influence their prescribing habits, as well as highly valued when delivered by email, it is clear to see the opportunity scientific content presents.
Tangent90 enables pharma to share published copyright scientific content. Already widely used in commercial, there has been an uplift in medical use. Key licensed papers can be shared via Approved Email, at medical congresses, or from the pharma portal.
An important factor in our ability to deliver high-quality solutions is our status as a Silver Certified Veeva Technology Partner. All of our solutions align with Veeva CRM, feeding all interaction data back into pharma’s existing systems. This provides pharma with valuable insights about every interaction and, enables them to tailor future communications, helping inform the next-best action approach.
To find out more about how Tangent90 can support you to manage your scientific content distribution, please contact us at hello@tangent90.com.
